You are here

  • Home
  • Archive
  • Volume 12, Issue 4
  • Once daily oral controller therapy with low dose theophylline or montelukast was not effective in poorly controlled asthma

Article Text

Article menu
Download PDFPDF
Therapeutics
Once daily oral controller therapy with low dose theophylline or montelukast was not effective in poorly controlled asthma

https://doi.org/10.1136/ebm.12.4.115

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007;175:235–42.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In patients with poorly controlled asthma while taking medication, what is the effectiveness of adding once daily oral controller therapy to low dose theophylline or montelukast?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★☆☆ Respirology ★★★★★★☆ Allergy & immunology ★★★★★☆☆

    METHODS

    Embedded ImageDesign:

    randomised placebo controlled trial.

    Embedded ImageAllocation:

    {concealed*}†.

    Embedded ImageBlinding:

    blinded (clinicians, patients, {data collectors, outcome assessors, and data safety and monitoring committee}†).*

    Embedded ImageFollow up period:

    24 weeks.

    Embedded ImageSetting:

    19 American Lung Association Asthma Clinical Research Centres (ALA-ACRC) in the US.

    Embedded ImagePatients:

    489 patients ⩾15 years of age (mean age 40 y, 74% women, 61% white) who were diagnosed with asthma, were prescribed daily asthma medication for ⩾1 year, had FEV1 ⩾50% of the predicted value, and had poor asthma control (score ⩾1.5 on the Asthma Control Questionnaire [ACQ]). Patients continued their baseline medications. Exclusion criteria were use of oral corticosteroids, leukotriene antagonists, or theophylline within 4 weeks before randomisation; ⩾20 …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • ↵† Information provided by author.

    • For correspondence: Dr R A Wise, Johns Hopkins Asthma & Allergy Center, Baltimore, MD, USA. rwise{at}jhmi.edu

    • Sources of funding: American Lung Association and Merck Company Foundation.